# Aln-cideb PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aln-cideb

> The next catalyst for aln-cideb, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Jan to Apr 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | aln-cideb |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Alcohol-Associated Liver Disease](https://sec-api.dev/indications/alcohol-associated-liver-disease), [Metabolic Dysfunction-Associated Steatohepatitis](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatohepatitis), [Metabolic Dysfunction-Associated Steatotic Liver Disease](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatotic-liver-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatohepatitis; MASH.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07631637 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07631637

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatohepatitis; MASH.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07631637 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07631637

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07854782 (Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07854782

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07854782 (Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07854782

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Alcohol-Associated Liver Disease; ALD.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07933328 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07933328

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Alcohol-Associated Liver Disease; ALD.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07933328 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07933328

## Same indication

- [Aro-inhbe](https://sec-api.dev/pdufa/aro-inhbe) (ARWR)
- [Efimosfermin](https://sec-api.dev/pdufa/efimosfermin) (GSK)
- [Efinopegdutide](https://sec-api.dev/pdufa/efinopegdutide) (MRK)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aln-cideb.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Aln-cideb PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aln-cideb

```bibtex
@misc{secapidev_pdufa_aln_cideb_20261116,
  title        = {Aln-cideb PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aln-cideb}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aln_cideb_20261116","title":"Aln-cideb PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aln-cideb","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
